Fresenius SE & Co. KGaA (FRA:FRE) received a €65.00 ($76.47) price target from analysts at Warburg Research in a report issued on Tuesday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the stock. Warburg Research’s price target suggests a potential upside of 81.16% from the stock’s previous close.
Other equities analysts have also issued reports about the stock. Sanford C. Bernstein set a €41.00 ($48.24) price objective on shares of Fresenius SE & Co. KGaA and gave the company a “buy” rating in a research report on Tuesday, February 9th. Berenberg Bank set a €55.95 ($65.82) price objective on Fresenius SE & Co. KGaA and gave the company a “buy” rating in a report on Friday. UBS Group set a €40.00 ($47.06) price target on Fresenius SE & Co. KGaA and gave the company a “neutral” rating in a report on Tuesday, November 24th. The Goldman Sachs Group set a €47.00 ($55.29) price objective on Fresenius SE & Co. KGaA and gave the stock a “buy” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. set a €50.00 ($58.82) target price on shares of Fresenius SE & Co. KGaA and gave the stock a “buy” rating in a research report on Wednesday, February 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the stock. Fresenius SE & Co. KGaA presently has an average rating of “Buy” and an average price target of €46.28 ($54.45).
FRA FRE opened at €35.88 ($42.21) on Tuesday. The business’s 50-day moving average price is €37.30 and its 200 day moving average price is €37.55. Fresenius SE & Co. KGaA has a 52-week low of €60.16 ($70.78) and a 52-week high of €80.00 ($94.12).
About Fresenius SE & Co. KGaA
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.